|
86 Companies |
|
134 Products |
|
134 Products |
|
85 Mechanisms of Action |
|
5 Trials |
|
1881 News |
|
| «12...678910111213141516...3738» |
- || Enrollment closed: CM ETG: Contingency Management of Alcohol Abuse in the Severely Mentally ILL (clinicaltrials.gov) - Jun 18, 2015
P=N/A, N=120, Active, not recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting
- Enrollment closed: Clinical Monitoring to Facilitate Continuous Care for Substance Abusing Clients (clinicaltrials.gov) - Jun 18, 2015
P=N/A, N=175, Active, not recruiting, Sponsor: Treatment Research Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Rykindo (risperidone extended release microspheres) / Luye Group
Trial completion: An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Jun 18, 2015
P1, N=16, Completed, Sponsor: Luye Pharma Group Ltd.
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- Trial primary completion date, Adherence: Effectiveness of Adherence Therapy for Schizophrenia (clinicaltrials.gov) - Jun 17, 2015
P1/2, N=134, Recruiting, Sponsor: The Hong Kong Polytechnic University
Enrolling by invitation --> Completed Trial primary completion date: May 2015 --> Aug 2015
- | risperidone / Generic mfg., paliperidone extended release / Generic mfg.
Enrollment closed, Enrollment change: A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia (clinicaltrials.gov) - Jun 16, 2015
P4, N=17, Active, not recruiting, Sponsor: Johnson & Johnson Taiwan Ltd
Trial primary completion date: May 2015 --> Aug 2015 Recruiting --> Active, not recruiting | N=50 --> 17
- || Trial primary completion date: Effects of a Walking Program in People With Mental Disorders (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=100, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Recruiting --> Active, not recruiting | N=50 --> 17 Trial primary completion date: Dec 2014 --> Dec 2015
- Trial primary completion date: Cognitive Remediation of Schizophrenia in a Community Mental Health Setting (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=120, Recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: May 2015 --> Nov 2015
- Trial primary completion date: Cognitive Remediation for First Episode of Psychosis Patients (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=48, Recruiting, Sponsor: University of Manchester
Trial primary completion date: May 2015 --> Nov 2015 Trial primary completion date: Mar 2015 --> Jul 2015
- valacyclovir / Generic mfg.
Trial primary completion date: Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia (clinicaltrials.gov) - Jun 11, 2015
P4, N=156, Enrolling by invitation, Sponsor: University of Pittsburgh
Trial primary completion date: Mar 2015 --> Jul 2015 Trial primary completion date: Feb 2015 --> Nov 2015
- Trial primary completion date: Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=72, Recruiting, Sponsor: National Institute of Mental Health (NIMH)
Trial primary completion date: Feb 2015 --> Nov 2015 Trial primary completion date: Jul 2017 --> Jul 2015
- || Trial primary completion date: CM ETG: Contingency Management of Alcohol Abuse in the Severely Mentally ILL (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=120, Recruiting, Sponsor: University of Washington
Trial primary completion date: Jul 2017 --> Jul 2015 Trial primary completion date: Dec 2014 --> Sep 2015
- Trial primary completion date: Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=65, Active, not recruiting, Sponsor: Research Foundation for Mental Hygiene, Inc.
Trial primary completion date: Dec 2014 --> Sep 2015 Trial primary completion date: Jun 2013 --> Jan 2015
- Trial primary completion date: Effectiveness of Neuroadaptive Cognitive Training in Adolescents at Risk for Psychosis (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=100, Recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Jun 2013 --> Jan 2015 Trial primary completion date: Mar 2015 --> May 2016
- aripiprazole / Generic mfg., risperidone / Generic mfg.
Trial primary completion date: Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis (clinicaltrials.gov) - Jun 11, 2015
P4, N=242, Active, not recruiting, Sponsor: North Shore Long Island Jewish Health System
Trial primary completion date: Mar 2015 --> May 2016 Trial primary completion date: Feb 2014 --> Dec 2014
- bupropion sustained-release / Generic mfg.
Trial termination: Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia (clinicaltrials.gov) - Jun 11, 2015
P4, N=17, Terminated, Sponsor: Massachusetts General Hospital
Trial primary completion date: Feb 2014 --> Dec 2014 Completed --> Terminated
- Trial termination: FROPS: Functional Rehabilitation for Older Patients With Schizophrenia (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=107, Terminated, Sponsor: Department of Veterans Affairs
Completed --> Terminated Completed --> Terminated; Loss of funding
- Trial initiation date, Trial primary completion date: Non-Invasive Brain Stimulation for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=50, Not yet recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Completed --> Terminated; Loss of funding Initiation date: Nov 2014 --> Sep 2015 | Trial primary completion date: Dec 2015 --> Dec 2016
- Trial initiation date, Trial primary completion date: SPA: A System for Preference Assessment in Mental Health (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=95, Not yet recruiting, Sponsor: University of California, Los Angeles
Initiation date: Nov 2014 --> Sep 2015 | Trial primary completion date: Dec 2015 --> Dec 2016 Initiation date: Aug 2014 --> Jul 2015 | Trial primary completion date: Jul 2015 --> Dec 2015
- Enrollment change, Trial primary completion date: CAST: Optimizing Cognitive Remediation Outcomes in Schizophrenia (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=160, Recruiting, Sponsor: University of California, San Francisco
Initiation date: Aug 2014 --> Jul 2015 | Trial primary completion date: Jul 2015 --> Dec 2015 N=80 --> 160 | Trial primary completion date: Apr 2015 --> Dec 2015
- || sodium valproate / Generic mfg.
Trial primary completion date: Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia (clinicaltrials.gov) - Jun 11, 2015
P4, N=100, Enrolling by invitation, Sponsor: University of Pittsburgh
N=80 --> 160 | Trial primary completion date: Apr 2015 --> Dec 2015 Trial primary completion date: Feb 2015 --> Feb 2016
- ||| Trial completion: Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia (clinicaltrials.gov) - Jun 11, 2015
P1, N=68, Completed, Sponsor: University of North Carolina, Chapel Hill
Trial primary completion date: Feb 2015 --> Feb 2016 Active, not recruiting --> Completed
- acetylcysteine solution / Generic mfg.
Trial completion: NACSZ: N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia (clinicaltrials.gov) - Jun 4, 2015
P1, N=26, Completed, Sponsor: VA Greater Los Angeles Healthcare System
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed, Trial primary completion date: Yoga as Cognitive Remediation in Schizophrenia (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=258, Active, not recruiting, Sponsor: Dr. Ram Manohar Lohia Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2015
- ||| Trial completion, Enrollment change: Life Quality and Health in Patients With Klinefelter Syndrome (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=452, Completed, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2015 Enrolling by invitation --> Completed | N=1350 --> 452
- |||| Trial completion: Helping Those With Mental Illness Quit Smoking (clinicaltrials.gov) - Jun 2, 2015
P4, N=272, Completed, Sponsor: University of Wisconsin, Madison
Enrolling by invitation --> Completed | N=1350 --> 452 Active, not recruiting --> Completed
- Trial completion: Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia (clinicaltrials.gov) - May 29, 2015
P2, N=19, Completed, Sponsor: Federal University of Rio Grande do Sul
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment open, Trial primary completion date, Adherence: SPERA-S: Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia (clinicaltrials.gov) - May 28, 2015
P=N/A, N=280, Recruiting, Sponsor: University of Cagliari
Recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2013 --> Jun 2015
- | acetylcysteine oral / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: NACPSY: N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis (clinicaltrials.gov) - May 28, 2015
P4, N=20, Completed, Sponsor: Beth Israel Deaconess Medical Center
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2013 --> Jun 2015 Recruiting --> Completed | N=33 --> 20 | Trial primary completion date: May 2014 --> Aug 2014
- Trial completion: EXERCISE-II: Enhancing Synaptic Plasticity and Cognition in Schizophrenia (clinicaltrials.gov) - May 27, 2015
P=N/A, N=66, Completed, Sponsor: University Medical Center Goettingen
Recruiting --> Completed | N=33 --> 20 | Trial primary completion date: May 2014 --> Aug 2014 Active, not recruiting --> Completed
- ||||||| asenapine / Generic mfg., olanzapine / Generic mfg.
Trial completion, Enrollment change: Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689) (clinicaltrials.gov) - May 27, 2015
P3, N=105, Completed, Sponsor: Forest Laboratories
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=170 --> 105
- Trial completion: Factors Association With Poor Physical Function in Older Adults With Schizophrenia (clinicaltrials.gov) - May 27, 2015
P=N/A, N=46, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed | N=170 --> 105 Active, not recruiting --> Completed
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Enrollment closed: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - May 27, 2015
P3, N=700, Active, not recruiting, Sponsor: FORUM Pharmaceuticals Inc
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Enrollment closed: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - May 27, 2015
P3, N=700, Active, not recruiting, Sponsor: FORUM Pharmaceuticals Inc
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| olanzapine / Generic mfg., amisulpride / Generic mfg.
Trial completion, Trial primary completion date: Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia (clinicaltrials.gov) - May 27, 2015
P=N/A, N=351, Completed, Sponsor: Technische Universit
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Feb 2015 --> Mar 2014
- | Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes
Trial completion: OLE: A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) (clinicaltrials.gov) - May 19, 2015
P3, N=478, Completed, Sponsor: Alkermes, Inc.
Recruiting --> Completed | Trial primary completion date: Feb 2015 --> Mar 2014 Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia (clinicaltrials.gov) - May 19, 2015
P1/2, N=144, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=80 --> 144 | Trial primary completion date: Aug 2012 --> Feb 2015
- |||||| Enrollment open, Head-to-Head: TaSCS: Task Sharing for the Care of Severe Mental Disorders in a Low-income Country (clinicaltrials.gov) - May 13, 2015
P3, N=324, Recruiting, Sponsor: University of Cape Town
Active, not recruiting --> Completed | N=80 --> 144 | Trial primary completion date: Aug 2012 --> Feb 2015 Not yet recruiting --> Recruiting
- ||||||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Trial completion: Aripiprazole Once-monthly in Patients With Schizophrenia (clinicaltrials.gov) - May 12, 2015
P3, N=88, Completed, Sponsor: H. Lundbeck A/S
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial completion, Enrollment change, Trial primary completion date: EQUATOR: Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia (clinicaltrials.gov) - May 8, 2015
P3, N=524, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Completed Recruiting --> Completed | N=420 --> 524 | Trial primary completion date: May 2016 --> Feb 2015
- Enrollment change, Trial withdrawal: Usability of a Website for People With Schizophrenia (clinicaltrials.gov) - May 7, 2015
P=N/A, N=0, Withdrawn, Sponsor: National Institute of Mental Health (NIMH)
Recruiting --> Completed | N=420 --> 524 | Trial primary completion date: May 2016 --> Feb 2015 N=75 --> 0 | Terminated --> Withdrawn
- Trial completion, Trial initiation date, Trial primary completion date: Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia (clinicaltrials.gov) - May 7, 2015
P2, N=103, Completed, Sponsor: The University of Hong Kong
N=75 --> 0 | Terminated --> Withdrawn Active, not recruiting --> Completed | Initiation date: Feb 2012 --> Jan 2013 | Trial primary completion date: Oct 2014 --> Apr 2014
- Enrollment change, Trial primary completion date: Effects of Systematic Patient Feedback on Therapy Outcome (clinicaltrials.gov) - May 6, 2015
P=N/A, N=170, Recruiting, Sponsor: Norwegian University of Science and Technology
Active, not recruiting --> Completed | Initiation date: Feb 2012 --> Jan 2013 | Trial primary completion date: Oct 2014 --> Apr 2014 N=120 --> 170 | Trial primary completion date: Jun 2016 --> Jun 2018
- Trial completion: Nonconvulsive Electrotherapy: a Proof-of-concept Trial (clinicaltrials.gov) - May 6, 2015
P1, N=13, Completed, Sponsor: University of Maryland
N=120 --> 170 | Trial primary completion date: Jun 2016 --> Jun 2018 Active, not recruiting --> Completed
- |||| Doria (risperidone extended release) / ROVI Pharmaceuticals Laboratories
Trial completion: PRISMA-2: Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia (clinicaltrials.gov) - May 5, 2015
P2, N=70, Completed, Sponsor: Rovi Pharmaceuticals Laboratories
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Daliresp (roflumilast) / AstraZeneca, Takeda, AbbVie
Enrollment closed, Trial primary completion date: Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia (clinicaltrials.gov) - May 5, 2015
P1, N=20, Active, not recruiting, Sponsor: Takeda
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Jun 2015
- |||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion: A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics (clinicaltrials.gov) - May 4, 2015
P4, N=617, Completed, Sponsor: Xian-Janssen Pharmaceutical Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Jun 2015 Active, not recruiting --> Completed
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial primary completion date: ACLAIMS: A Comparison of Long-acting Injectable Medications for Schizophrenia (clinicaltrials.gov) - May 2, 2015
P4, N=311, Active, not recruiting, Sponsor: New York State Psychiatric Institute
Active, not recruiting --> Completed Trial primary completion date: Dec 2013 --> Jul 2013
- || risperidone / Generic mfg.
Trial primary completion date: Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia (clinicaltrials.gov) - Apr 29, 2015
P2, N=282, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Dec 2013 --> Jul 2013 Trial primary completion date: Jan 2009 --> Oct 2005
- | citalopram / Generic mfg., methylphenidate tablet / Generic mfg.
Trial completion: Methylphenidate for Depressed Cancer Patients Receiving Palliative Care (clinicaltrials.gov) - Apr 29, 2015
P=N/A, N=47, Completed, Sponsor: Department of Veterans Affairs
Trial primary completion date: Jan 2009 --> Oct 2005 Active, not recruiting --> Completed
- Abilify MyCite (aripiprazole tablets embedded with sensor) / Otsuka
Trial primary completion date, Adherence: Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder (clinicaltrials.gov) - Apr 28, 2015
P2, N=0, Withdrawn, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Active, not recruiting --> Completed Trial primary completion date: Oct 2014 --> May 2014